BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190925
DTEND;VALUE=DATE:20190927
DTSTAMP:20260515T013938
CREATED:20190402T114527Z
LAST-MODIFIED:20190402T114527Z
UID:20170-1569369600-1569542399@www.pharmajournalist.com
SUMMARY:Biobanking 2019
DESCRIPTION:With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020\, backed by an explosive CAGR of 9.5% between now and 2026. This market growth is fuelled by the increasing drive towards precision and personalised medicine and thus\, quality biosamples are now in soaring demand. \n \nCome join us in September 2019 and; thoroughly understand the latest developments in the biobanking industry; network with the industry experts and key opinion leaders; gain insight into how the biobanking industry at the forefront at driving precision medicine and enhancing research and discover ‘Drone4Care’\, how drone delivery of biosamples can be a reality. \nThe event will bring together internationally recognised biorepositories\, scientific pioneers from pharmaceutical companies\, and academics to strengthen current knowledge in biosample management and their research applications. We will cover the most relevant hot topics including: the latest biorepository technological breakthroughs\, the best practices in biobanking\, shifts in the biosample regulation landscape\, the international biobank societies with ESBB and ISBER\, along with a whole host of successful biobanking business model structures to help reinvigorate your biobank.  \nBenefits of attending: \n\nDiscover ‘Drone4care’ from Laurent Dollé\, the innovative and daring plan to use drones for the delivery of biomaterial. Additionally\, he will be detailing the new promising technology of Tissue Microarray\, a bioprocessing technology that can reduced the number of needed biosamples for research from 200 down to 1\n\n\nHear from UK Biobank on the continual impact of GDPR on the biobanking landscape\n\n\nLearn about a diverse range of the most successful biobanking business models from real case studies\n\n\nGain insight from the global biobank collaboration societies of ESBB and ISBER\, see how you can place your biobank on the international stage\n\nView the full agenda online: \nEarly bird rates: \n\nBOOK BY 30TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY THE 28TH JUNE AND SAVE £200\n\nPlus\, two interactive half day pre-conference workshops: \nWorkshop A: Enhance your biobank’s commercial prowess through the application of financial and economic tools along with how to improve your biosamples data quality\nWorkshop Leader: Laurent Dollé\, Managing Director\, BWB (Biothèque Wallonie Bruxelles)\n8.30 – 12.30 \nWorkshop B: The Organic Development of a Sustainable Academic Biobank\nWorkshop Leader: Mary-Beth Joshi\, Director\, Biobank & translational Research Core\, Duke University Medical Centre\n1.30 – 5.30 \nFollow us:  @SMiPharm #smibiobanking \nTo learn more and to register online\, visit www.biobanking-event.com/Pharmajwl
URL:https://www.pharmajournalist.com/event/biobanking-2019/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190925
DTEND;VALUE=DATE:20190927
DTSTAMP:20260515T013938
CREATED:20190404T105139Z
LAST-MODIFIED:20190404T105139Z
UID:20198-1569369600-1569542399@www.pharmajournalist.com
SUMMARY:SMi’s 10th Annual Biosimilars Conference
DESCRIPTION:Conference:  Wednesday 25 and Thursday 26 September 2019\nWorkshop: Tuesday 24th September 2019 \nChaired by Michel Mikhail\, International Expert Regulatory Affairs\, Global Expert Biosimilars \nDiscussing future regulatory\, commercial and legal challenges of biosimilars \nSMi Group are delighted to announce the 10th annual Biosimilars Conference taking place on 25th and 26th September 2019. This year’s event will be our first global event taking place in London\, UK. The event’s focus is to highlight the current challenges in the biosimilars market and discuss current undergoing plans or developments to overcome these challenges. \nThe biosimilars market is forecasted to reach USD$23.6B by 2023 at a compound annual growth rate (CAGR) of 31.70%. Factors driving the increase of this market include growing demand for biosimilar drugs due to their cost-effectiveness\, growing incidence of chronic diseases\, and strategic collaborations resulting in enhanced productivity and clinical trial activities. \nWith the expiry dates of major patents fast approaching\, the emerging gap in the market for biosimilars is now a major attraction for manufacturers. As the availability of biosimilars could potentially reduce direct spending by USD$54B by 2026\, the question is what can current biosimilar producing companies do to join this market to benefit the patients\, physicians and investors? \n BENEFITS OF ATTENDING \n\nHEAR about current strategies under development to overcome challenges with patents currently faced by many biosimilar developers\nDISCUSS the possible changes in regulatory approval of biosimilars in the UK post Brexit\, and how this will impact market entry\nEXPLORE the latest methods in use to maintain the relationship between stakeholders\, doctors and patients\, with the influence of governing bodies\nREVIEW FDA regulations for the approval of Biosimilars and the latest approvals\n\nPLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS\nTuesday 24th September 2019\, Copthorne Tara Hotel\, Central London\, UK \nA: US-FDA Interchangeability Guideline\n08.30 – 12.30\nWorkshop Leader: Michel Mikhail\, International Expert Regulatory Affairs\, Global Expert of Biosimilars \nB: Global Development of Biosimilars – what can the US learn from Europe’s Strategies to promote biosimilar uptake\n13:30 – 17:30\nWorkshop Leader: Rodeina Challand\, General Manager\, Challand Biosimilar Consulting \nWHO SHOULD ATTEND? \nPresidents\, Vice Presidents\, Managing Directors\, Directors\, Associate Directors\, Chiefs\, Heads\, Principals\, Managers and Analysts of: \n\nBiosimilar Development\nProduct Development\nCommercialization\nMarket Access\nMedical Affairs\nIntellectual Property\nBioloigcs\nBiopharmaceuticals\nResearch and Development\nGenerics\nBiobetters\nBusiness Development\nStrategic Marketing\nDrug Development\nClinical Trials\nImmunogenicity Studies\n\nGlobal Presence: Attendees from all over the world attend our events. Gain hands on insight from representatives from UK\, Europe and USA. \nEARLY BIRD-RATES \n\nBOOK BY 30TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 28TH JUNE AND SAVE £200
URL:https://www.pharmajournalist.com/event/smis-10th-annual-biosimilars-conference/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR